Articles Tagged With:
-
Adolescent Pregnancy
Adolescent pregnancy is shaped by socioeconomic disadvantage, rural residence, early marriage, history of abuse, and limited contraceptive access. These factors increase the risk for anemia, stillbirth, preeclampsia, preterm birth, and low birthweight in adolescent mothers. Meaningful reduction requires coordinated, multisectoral action, with targeted educational and reproductive health interventions focused on adolescents.
-
Does Thoracentesis Speed Recovery from Heart Failure?
An unblinded, multicentered, randomized trial of patients with acute heart failure hospital admissions and significant pleural effusions showed that early thoracentesis, in addition to recommended medical therapy, did not reduce mortality or length of stay, or increase days alive out of the hospital for 90 days. However, it was relatively safe and could be employed in selected persistently symptomatic patients with very large effusions.
-
Echocardiography vs. CMR for Quantitating Aortic Regurgitation
A small study of echocardiography compared to cardiac magnetic resonance (CMR) imaging in patients with chronic aortic regurgitation of variable severity has shown that the simple use of the color Doppler regurgitant jet vena contracta width and the end-diastolic left ventricular volume index by two-dimensional echocardiographic imaging can accurately predict who has clinically significant regurgitation.
-
Stroke Risk in Patients with New AF During Hospitalization for Other Reasons
In a Canadian administrative database study of patients who developed atrial fibrillation during a hospitalization for other reasons, researchers followed the patients for one year to ascertain the risk of subsequent stroke. The incidence of stroke in those not anticoagulated generally was below the 2% per year threshold recommended for treatment with anticoagulants. However, in those with a CHA2DS2-VA score ≥ 5 (sex not included based on new data) and in those admitted for cardiac medical problems, the 95% confidence intervals of stroke risk did cross 2%. Thus, selected patients may be candidates for anticoagulation.
-
Best Long-Term Antiplatelet Monotherapy Post-PCI
In a multicenter, randomized, open-label trial of clopidogrel vs. aspirin monotherapy in patients post-percutaneous coronary intervention (PCI) who had been on dual antiplatelet therapy for the recommended period, those randomized to clopidogrel showed fewer major cardiovascular or cerebral events over a two-year follow-up period than those on aspirin without an increase in bleeding events.
-
Favorable One-Year Results Reported from the LuX TTVR Device
One-year results from the TRAVEL study of the LuX transcatheter tricuspid valve replacement (TTVR) device demonstrates sustained reduction of tricuspid regurgitation to mild or less in more than 95% of patients, with improved functional status and reverse remodeling of the right ventricle.
-
And Then What Happens?
You are consulted on the electrocardiogram (ECG) in the figure — but without the benefit of any clinical information. This tracing was assessed as showing AFib (atrial fibrillation) with a controlled ventricular response. Do you agree?
-
Vimseltinib (Romvimza) Capsules for TGCT
The U.S. Food and Drug Administration has approved vimseltinib for the treatment of tenosynovial giant cell tumor for which surgical resection is not desirable.
-
Paxlovid: Is It Still Worth the Cost?
Paxlovid is one of the most effective antivirals developed during the COVID-19 years, demonstrating significant reductions in hospitalization and death in higher-risk persons, as well as the time to viral elimination. However, it does not shorten the duration of symptoms, and there is little evidence that Paxlovid reduces the risk of developing long COVID symptoms.
-
The Effect of High-Dose Vitamin D on Clinically Isolated Syndrome and MS
This study by Thouvenot et al evaluated the effectiveness of high-dose vitamin D treatment on clinically isolated syndrome and early multiple sclerosis as monotherapy and reported a reduced incidence of new disease activity compared to the control group.